论文信息 - 802PPatient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial - 字舞流文

802PPatient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial

S. Culine | G. Gravis | P. Barthélémy | C. Théodore | K. Fizazi | P. Beuzeboc | I. Borget | J. Berdah | Y. Tazi | G. Baciarello | M. Deblock | G. Martineau | R. Delva | T. N. T. Hon | C. Cheneau | A. Flechon | E. Bompas | M. Gross‐Goupil | F. J. Lobbedez | T. Lharidon